

THC BioMed Form 7

MONTHLY PROGRESS REPORT

December 2022

Name of CSE Issuer **THC BioMed Intl Ltd. ("THC BioMed")**
Trading Symbol: **THC**
Number of Outstanding Listed Securities **163,938,556 common shares and 15,534,285 reserved for Issuance**
Date: **January 6, 2022**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

In December 2022, the Issuer announced that it acquired a 40% share in an Asian company that is licensed to grow and sell medical cannabis in that country. The Company also announced that it completed construction of the grow facility in Asia has begun to grow cannabis in that new facility.

On December 29, the Issuer provided a summary for the three months ended October 31, 2022, which reads in part as follows:

Q1 HIGHLIGHTS

- The Company reported a gross profit before fair value adjustments for the three months ended October 31, 2022 of \$275,934 or 41%
- The Company reported a gross profit after fair value adjustments for the three months ended October 31, 2022 of \$180,951 or 27%
- Sales of the Company's newly developed line of CBD products began
- Sale of edibles made up 31% of total sales in Q1
- Identified and began construction of medical cannabis Grow facility in Asia.

HIGHLIGHTS SUBSEQUENT TO OCTOBER 31, 2022

- On December 28, 2022, THC Kiss Cocoa Biscuits were #1 on the bestselling edibles list on the Ontario Cannabis Store website.
- On December 28, 2022, THC Kiss Shortbread Biscuits were #1 on the bestselling edibles list on the BC Cannabis Store website.
- On December 28, 2022, THC Kiss Mango Beverage Shots and THC Kiss Guava Beverage Shots were #1 and #2 on the bestselling beverages list on the Ontario Cannabis Store website.
- On December 28, 2022, THC Kiss Mango Beverage Shots were #6 on the bestselling edibles list on the BC Cannabis Store website and the Headset website.
- Due to the high demand of the Company's Kiss Beverage Shot, the Company began automating its beverage production line.

“The loss at October 31, 2022 is significant due to factors affecting the fair value changes of the biological assets and inventory (\$94,983), cost of sales (\$391,942) and expenses (\$497,799). We are continually working to create production efficiencies and lower costs,” said THC BioMed President and CEO, John Miller. “Going forward, we intend to concentrate on the edibles market and specifically our THC Beverage Shot, THC Kiss Gummies, and THC Kiss Biscuits which will improve our gross margin and, we believe, our subsequent bottom line.”

2. Provide a general overview and discussion of the activities of management.

Management worked on the realization of the company’s business plan, including production line expansion and automation and new production for the legal cannabis market in Asia.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The issuer began to grow cannabis in the new grow facility in Asia. The Issuer owns 40% of the Asian company that owns the new facility and has the legal right to grow and sell cannabis.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer acquired 40% of a company in Asia for nominal consideration. The company is working the Issuer to grow and sell legal cannabis in Asian markets.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

The Issuer has continued to register new patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

None.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer's most recent Management's Discussion and Analysis under the titles

“Financial Instruments and Risk Management” and “Other Risks and Uncertainties”, which is available on SEDAR at www.sedar.com.

The outbreak of COVID-19 has significantly increased economic uncertainty. In addition, public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions and the adoption of remote working, have impacted our business and operations. COVID-19 is impacting our contractors’ ability to provide services to us, including professional services such as accounting and auditing due to social distancing measures.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **January 6, 2022**

John Miller

Name of Director or Senior Officer

“John Miller”

Signature

President and CEO

Official Capacity

Issuer Details		
Name of Issuer: THC BioMed Intl Ltd.	For Month End December	Date of Report: YYYYMMDD 2023/01/06
Issuer Address: P.O. Box 20033 Towne Centre		

City/Province/Postal Code: Kelowna, BC V1Y 9H2	Issuer Fax No.: N/A	Issuer Telephone No. (250) 870-2512
Contact Name: John Miller	Contact Position: President & CEO	Contact Telephone No. (250) 870-2512
Contact Email Address: info@thcbiomed.com	Web Site Address: www.thcbiomed.com	